Retraction
Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity
Paper Information
Record ID:
35644
Author(s):
Journal:
Publication Date:
September 27, 2019
Retraction Date:
February 23, 2022
(3.7 years years ago)
Subjects:
Institution:
Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Qld, AustraliaCountry:
🇦🇺 AustraliaArticle Type:
Publisher:
Wiley
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (27)
27
Total Citations9
Post-Retraction(33.3%)
18
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
2
Within 30 days
5
Within 1 year
2
After 2+ years
1112
Days since retraction (latest)
Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis
Zheng Gu, Erle Deng, Jing Ai et al. (6 authors)
Discover Oncology
Open Access
Published: Mar 2025
1112 days after retraction
Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements
Zhen Wang, Yanqi Song, Honglei Guo et al. (6 authors)
Current Treatment Options in Oncology
Published: Jan 2025
1073 days after retraction
Bispecific Antibodies: An Emerging Concept in Antibody-Based Cancer Therapies
Rafael Oliveira BrandĂŁo, Xin Jiang, Sudhagar Selvaraju et al. (4 authors)
Unknown Journal
Published: Jan 2024
677 days after retraction
Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
Qingxu Liu, L. Li, Qin Wan et al. (4 authors)
Cancer Biology and Medicine
Open Access
Published: Nov 2023
3 citations
3 citations
621 days after retraction
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
Francesco Pantano, Flavia Tramontana, Michele Iuliani et al. (15 authors)
Journal of bone oncology
Open Access
Published: Oct 2022
16 citations
16 citations
247 days after retraction
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Î’ ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
Sonia Simonetti, Michele Iuliani, Marco Stellato et al. (8 authors)
Journal for ImmunoTherapy of Cancer
Open Access
Published: Sep 2022
12 citations
12 citations
190 days after retraction
Strategies for developing PD-1 inhibitors and future directions
Wensheng Chen, Yuan Huang, Wenting Pan et al. (5 authors)
Biochemical Pharmacology
Open Access
Published: May 2022
24 citations
24 citations
94 days after retraction
Bispecific Antibodies Progression in Malignant Melanoma
Juan Tang, Youling Gong, Xuelei Ma
Frontiers in Pharmacology
Open Access
Published: Mar 2022
6 citations
6 citations
28 days after retraction
Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis
Bo Li, Pengru Wang, Jian Jiao et al. (6 authors)
Frontiers in Immunology
Open Access
Published: Mar 2022
48 citations
48 citations
26 days after retraction
RANKL biology
Noriko Takegahara, Hyunsoo Kim, Yongwon Choi
Bone
Open Access
Published: Feb 2022
81 citations
81 citations
7 days before retraction
Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy
Antonella Cardinale, Carmen Dolores De Luca, Franco Locatelli et al. (4 authors)
Frontiers in Immunology
Open Access
Published: Nov 2021
26 citations
26 citations
91 days before retraction
Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry
Fabien Thoreau, Vijay Chudasama
RSC Chemical Biology
Open Access
Published: Oct 2021
14 citations
14 citations
124 days before retraction
Immuno-PET Molecular Imaging of RANKL in Cancer
Jonatan Dewulf, Christel Vangestel, Yannick Verhoeven et al. (8 authors)
Cancers
Open Access
Published: Apr 2021
3 citations
3 citations
299 days before retraction
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
Yichi Xu, Gendi Song, Shangdan Xie et al. (8 authors)
Molecular Therapy
Open Access
Published: Apr 2021
85 citations
85 citations
300 days before retraction
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma
Vito Vanella, Lucia Festino, Maria Grazia Vitale et al. (5 authors)
Expert Opinion on Emerging Drugs
Published: Mar 2021
18 citations
18 citations
351 days before retraction
Role of RANKL in cancer development and metastasis
Kazuo Okamoto
Journal of Bone and Mineral Metabolism
Published: Jan 2021
22 citations
22 citations
418 days before retraction
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
Marlena Surowka, Wolfgang Schaefer, Christian Klein
mAbs
Open Access
Published: Jan 2021
63 citations
63 citations
418 days before retraction
Atezolizumab alleviates the immunosuppression induced by PD‑L1‑positive neutrophils and improves the survival of mice during sepsis
Jianxin Chen, Ruiyuan Chen, Shaoxiong Huang et al. (5 authors)
Molecular Medicine Reports
Open Access
Published: Dec 2020
15 citations
15 citations
435 days before retraction
Antitumor immune responses induced by photodynamic and sonodynamic therapy: a narrative review
Hong Chen, Zhifei Dai
Journal of Bio-X Research
Open Access
Published: Dec 2020
4 citations
4 citations
442 days before retraction
The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL
Aristofania Simatou, Panagiotis Sarantis, Evangelos Koustas et al. (5 authors)
International Journal of Molecular Sciences
Open Access
Published: Oct 2020
23 citations
23 citations
497 days before retraction
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
Jie Ming, Shane J. F. Cronin, Josef Penninger
Frontiers in Oncology
Open Access
Published: Aug 2020
58 citations
58 citations
565 days before retraction
Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective
Maria V. Deligiorgi, Dimitrios T. Trafalis
Expert Opinion on Biological Therapy
Published: Jul 2020
6 citations
6 citations
590 days before retraction
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
Josée Golay, Alain E. Andrea
Antibodies
Open Access
Published: May 2020
18 citations
18 citations
644 days before retraction
Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054
Jorge Cebada, Amira Flores, Cindy Bandala et al. (6 authors)
Expert Opinion on Therapeutic Patents
Published: May 2020
13 citations
13 citations
651 days before retraction
Exploration of the personalized immune checkpoint atlas of plasma cell dyscrasias patients using high‑dimensional single‑cell analysis
Chenggong Tu, Yongjiang Zheng, Hui Zhang et al. (4 authors)
Oncology Reports
Open Access
Published: Apr 2020
3 citations
3 citations
673 days before retraction
Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
Lisa C. Holthof, Tuna Mutis
Cancers
Open Access
Published: Apr 2020
60 citations
60 citations
677 days before retraction
Structure and Optimization of Checkpoint Inhibitors
Sarah Picardo, Jeffrey Doi, Aaron R. Hansen
Cancers
Open Access
Published: Dec 2019
43 citations
43 citations
795 days before retraction
Quick Stats
Total Citations:
27
Years Since Retraction:
3.7 years
Open Access:
Yes
Last Checked:
Jul 24, 2025